Dimerix Limited (ASX: DXB)

Market Cap	273.34M
Revenue (ttm)	583.48K
Net Income (ttm)	-17.08M
Shares Out	557.83M
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,520,255
Average Volume	5,372,240
Open	0.495
Previous Close	0.490
Day's Range	0.470 - 0.495
52-Week Range	0.160 - 0.665
Beta	0.53
RSI	76.33
Earnings Date	Feb 20, 2025

About Dimerix

Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. The company develops DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 which is in phase 2 clinical trial for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for chronic obstructive pulmonary disease, as well as develops proprietary receptor- HIT assay technology. Dimerix Limited is headquartered in Fitzroy, Australia.

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Nina Webster
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: DXB

Financial Performance

In 2024, Dimerix's revenue was 583,478, an increase of 1486.10% compared to the previous year's 36,787. Losses were -17.08 million, 23.7% more than in 2023.